Letter to the editor: Atezolizumab plus bevacizumab for hepatocellular carcinoma in the real world

Hepatology. 2022 Oct;76(4):E84-E85. doi: 10.1002/hep.32588. Epub 2022 Jun 6.

Authors

Junwei Zhang¹, Jinyu Fang², Ziyu Xun¹, Yiyao Xu¹, Xin Lu¹, Haitao Zhao¹

Affiliations

¹ Department of Liver SurgeryState Key Laboratory of Complex Severe and Rare DiseasesPeking Union Medical College Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical CollegeBeijingChina.
² Department of Human Anatomy and Histology and EmbryologySchool of Basic Medical SciencesPeking University Health Science CenterBeijingChina.

PMID: 35604038
DOI: 10.1002/hep.32588

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab / therapeutic use
Carcinoma, Hepatocellular* / drug therapy
Humans
Liver Neoplasms* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
Bevacizumab
atezolizumab